New Zealand Faces Critical Medicine Shortages in Global Crisis, Study Warns

A new study reveals New Zealand is highly vulnerable to life-saving medicine shortages – including antibiotics and heart medications – should a major global event disrupt international trade routes.

Published today in The New Zealand Medical Journal, the research found that none of the ten most commonly prescribed pharmaceuticals in the country are manufactured domestically. These include paracetamol, amoxicillin, aspirin, and metoprolol. Researchers warn that a scenario like a nuclear war, pandemic, or significant regional conflict could quickly deplete existing stocks, leading to increased mortality rates from treatable conditions. This vulnerability highlights a growing reliance on global supply chains for essential healthcare.

The primary concern stems from New Zealand’s lack of petrochemical refining capabilities, a crucial step in producing the key ingredients for many of these drugs. “So that means that when existing stocks run out, we would no longer have any of these life-saving medicines, and we would see increased deaths from infections, heart disease, stroke and asthma,” explained Professor Nick Wilson of Otago University, a co-author of the study. The situation mirrors global trends, with Europe sourcing 60-80% of its generic medicine ingredients from China and the United States relying on overseas manufacturers for a significant portion of both brand and generic drugs – learn more about drug shortages from the FDA.

Potential solutions discussed in the study include strengthening agreements with Australia, which possesses petrochemical manufacturing, and exploring domestic production of alternative ingredients, such as salicylic acid from willow bark as a substitute for aspirin. Researchers also suggest investing in infrastructure for local production, potentially modifying existing plants or building a micro-refinery. However, authors note that a collaborative approach with Australia, including joint funding for pharmaceutical production and ensuring continued trans-Tasman trade, is the most sensible path forward. You can find more information on New Zealand’s Ministry of Health website.

Officials have indicated they are reviewing the study’s findings and will consider strategies to bolster medicine resilience in the coming months.